Shelter Pharma (BOM:543963) EBIT: ₹123.3 Mil (TTM As of Mar. 2026)


BOM:543963 Shelter Pharma Ltd BOM:543963
66 GF Score
Price ₹29.05
GF Value ₹57.84
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Shelter Pharma EBIT?

Shelter Pharma BOM:543963 +0.66% 66 EBIT is ₹123.3 Mil as of Mar. 2026. GuruFocus rates BOM:543963 with a GF Score™ of 66/100 and a GF Value™ of ₹57.84 (Possible Value Trap). The stock has 5 warning signs investors should review.

Shelter Pharma's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹62.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹123.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shelter Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 12.76%. Shelter Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 36.45%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shelter Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 25.53%.

Shelter Pharma  (BOM:543963) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shelter Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=124.886 * ( 1 - 27.11% )/( (608.204 + 819.004)/ 2 )
=91.0294054/713.604
=12.76 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=668.954 - 7.954 - ( 52.796 - max(0, 53.15 - 422.806+52.796))
=608.204

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=842.329 - 12.536 - ( 10.789 - max(0, 69.997 - 550.487+10.789))
=819.004

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shelter Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=125.11/( ( (68.059 + max(243.235, 0)) + (66.826 + max(308.414, 0)) )/ 2 )
=125.11/( ( 311.294 + 375.24 )/ 2 )
=125.11/343.267
=36.45 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(109.363 + 167.476 + 15.778) - (7.954 + 0 + 41.428)
=243.235

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(118.066 + 244.389 + 13.291) - (12.536 + 0 + 54.796)
=308.414

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shelter Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=123.322/483.105
=25.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shelter Pharma EBIT Related Terms

Shelter Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Shelter Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shelter Pharma EBIT Chart

Shelter Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 25.68 69.87 84.93 98.05 123.32

Shelter Pharma Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 43.27 48.01 50.04 60.77 62.56

BOM:543963 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shelter Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shelter Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shelter Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shelter Pharma's EV-to-EBIT falls into.


BOM:543963
66GF Score
Shelter Pharma Ltd BOM:543963
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shelter Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹123.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹123.3 Mil mean?
Shelter Pharma (BOM:543963) has a EBIT of ₹123.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shelter Pharma.
Is Shelter Pharma's EBIT too high?
Shelter Pharma's current EBIT is ₹123.3 Mil. Overall, Shelter Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shelter Pharma's EBIT compare to ZTS and UTHR?
Shelter Pharma's EBIT of ₹123.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shelter Pharma. Shelter Pharma's current EBIT is ₹123.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shelter Pharma stock overvalued right now?
Based on GuruFocus' analysis, Shelter Pharma (BOM:543963) is currently considered Possible Value Trap. The stock's GF Value™ is ₹57.84, compared to a current price of ₹29.05 — trading 49.8% below its estimated fair value. The current EBIT is ₹123.3 Mil. Shelter Pharma's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shelter Pharma (BOM:543963), the current EBIT is ₹123.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shelter Pharma (BOM:543963) Overvalued in 2026?

Based on GuruFocus' analysis, Shelter Pharma stock appears to be undervalued. The current stock price of ₹29.05 is trading 49.8% below its estimated GF Value™ of ₹57.84. GuruFocus considers Shelter Pharma to be Possible Value Trap.

Key valuation signals for BOM:543963:

  • EBIT: ₹123.3 Mil
  • GF Value™: ₹57.84 vs. price of ₹29.05 (49.8% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the BOM:543963 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shelter Pharma Business Description

Address Ashram Road, 5th Floor, 501 Sakar 4, Opposite MJ Library, Paldi, Ellisbridge, Ahmedabad, GJ, IND, 380006
Shelter Pharma Ltd focuses in manufacturing herbal products with a well-built presence in Human Pharma as well as the Veterinary space. It is present in majority of the non-critical segments of human and veterinary pharma through its well-spread portfolio. Its products include tablets, syrups, baby drops, barley water, oils, powders, ointments, etc.
66GF Score

Get the complete analysis for BOM:543963

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹29.05
Price
₹57.84
GF Value